ICT 107

Drug Profile

ICT 107

Alternative Names: Cancer vaccine - ImmunoCellular Therapeutics; Dendritic cell vaccines - ImmunoCellular Therapeutics; ICT-107

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes - Glioblastoma

Highest Development Phases

  • Suspended Glioblastoma

Most Recent Events

  • 21 Jun 2017 ICT 107 is available for licensing as of 21 Jun 2017. www.imuc.com
  • 21 Jun 2017 Suspended upon strategic review of financing and development strategies for ICT 107 - Phase-III for Glioblastoma (Combination therapy, First-line therapy) in Canada, USA, Austria, Germany, Netherlands and Spain (Intradermal)
  • 25 Jul 2016 ImmunoCellular Therapeutics receives regulatory approvals for a phase III trial in Glioblastoma Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top